Exact Sciences Corporation (NASDAQ:EXAS) is listed as one of the best strong buy growth stocks to invest in. Jefferies analyst Tycho Peterson reiterated a Buy rating on EXAS with a price target of $80.00. The company reported fiscal Q2 2025 earnings, revealing a record total revenue of $811 million, up 16% from the previous quarter. EXAS raised its full-year revenue and adjusted EBITDA guidance, along with announcing a multi-year productivity plan targeting $150 million in annual savings by 2026. EXAS focuses on early cancer detection and prevention through products like Cologuard and Oncotype DX. While EXAS shows potential, some AI stocks may offer greater upside and less risk.

Source: https://www.insidermonkey.com/

Read more at Yahoo Finance: Jefferies Reiterates a Buy Rating on Exact Sciences Corporation (EXAS)